Pĕnicková V, Jemelík R, Opavský J, Jezdinský J
Research Institute of Higher Nervous Activity, Palacký University, Olomouc, Czechoslovakia.
Acta Univ Palacki Olomuc Fac Med. 1990;128:37-47.
A group of 36 patients were tested for the effects of percutaneous iontophoretic application of Vinblastin inj., a microtubular transport inhibitor (Gideon Richter, Hungary) in the treatment of chronic intractable pain. The group is divided into two subgroups: (1) 16 patients with persistent root pain following one or more operations for lumbar intervertebral disk herniation. (2) 20 patients with persistent pain in the area of the radicular skin zones or in the skin innervation areas of peripheral nerves. Vinblastin was injected in the place of maximal pain, 0.01% concentration in the total amount of 5 mg of active substance. The active electrode was the anode. There were at least 15 procedures per patient. The therapeutic effect was evaluated from the patients' subjective reports on pain relief in per cent, from the intensity of actual pain and from the interference of pain intensity with daily activities. Considering all the criteria, an improvement was achieved in 29 cases, i.e. 81%. The beneficial effect of the therapy was observed from the 8th to 10th application. In the first group of patients, 69% showed a clinically significant relief of the algetic symptoms. In the other group, the therapeutic effect was 90% of cases. A significant difference between both these groups was found to be in the degree of pain relief after the end of therapy. In the first group the average pain relief was 22.2%, in the other one 47.7%. This difference is statistically highly significant. Except for one case, the beneficial effect was always recorded in the place of administration (under the anode). Apart from local skin irritation in 2 patients and spot burns under the electrode in 2, no other side adverse effects were seen in the course of therapy, after its termination or at the checks made after some time interval (maximum 3 years).
对36名患者进行了测试，以观察微管转运抑制剂长春碱注射液（匈牙利吉东·里奇特公司生产）经皮离子电渗疗法治疗慢性顽固性疼痛的效果。该组患者分为两个亚组：（1）16名患者在接受一次或多次腰椎间盘突出症手术后出现持续性根性疼痛。（2）20名患者在神经根皮肤区域或周围神经皮肤支配区域出现持续性疼痛。将长春碱注射到疼痛最剧烈的部位，活性物质总量为5mg，浓度为0.01%。活性电极是阳极。每位患者至少接受15次治疗。根据患者关于疼痛缓解百分比的主观报告、实际疼痛强度以及疼痛强度对日常活动的干扰来评估治疗效果。综合所有标准，29例患者病情得到改善，即81%。从第8次到第10次治疗观察到了该疗法的有益效果。在第一组患者中，69%的患者疼痛症状得到了临床上显著的缓解。在另一组中，治疗效果为90%的病例。发现这两组之间的显著差异在于治疗结束后的疼痛缓解程度。第一组的平均疼痛缓解率为22.2%，另一组为47.7%。这种差异在统计学上具有高度显著性。除1例患者外，有益效果总是出现在给药部位（阳极下方）。在治疗过程中、治疗结束后或经过一段时间间隔（最长3年）进行检查时，除2例患者出现局部皮肤刺激和2例电极下方出现点状烧伤外，未观察到其他不良副作用。
